Ensign Group price target raised to $150 from $135 at Truist

Truist raised the firm’s price target on Ensign Group to $150 from $135 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results in Healthcare Services. The sector offers “attractive core demand drivers”, ongoing M&A opportunity, and strong relative positioning, and while “ongoing selectivity” remains important, the firm remains bullish on the group’s long-term drivers – demographics, move to value-based care, and site of service redirection – underpinning its solid growth, the analyst tells investors in a research note. For the company, Truist sees continued sizable M&A opportunity given the strong balance sheets/cash flow generation and higher acuity offering.